Genovis Investor Relations Material
Latest events
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies
Latest reports from Genovis
Access all reports
Segment Data
Access more data
Net sales by
Product category
Enzyme
Antibodies
Expenses by
Financials
Genovis AB designs, develops, and sells tools for development of drugs for customers in the pharmaceutical and medical device industries. The company primarily provides site-specific polymerases, glycanases, antibodies, glycoengineered proteins, and other biopharmaceutical tools. It offers site-specific ADAMTS5 inhibitor; recombinant elastase with or without carbonyl-sulfonate glycosylation; recombinant neutrophil collagenase; recombinant rhinovirus 2C protease with 0 to 7 N-linked glycans; AA47G1; Nedd4 binding protein 2/Nedd4L RFP fusion protein; and monomeric red fluorescent protein variants. The company also provides antibodies, including renin activity assays; renin activity assay reagents; chymase activity assays; chymase activity assay reagents; as well as plasma renin activity tests. In addition, it offers GlycoSMART panels for deglycosylating individual glycoproteins for analysts at pharmaceutical and biotechnology companies engaged in glycoprotein production and analysis. The company sells its products through distributors in Sweden and internationally.
Latest articles
Four Decades of IPOs: An Overview
An overview of the stock and IPO market from the 80's until today, highlighting important events and trends.
24 Apr 2024
Larry Page: The Mastermind Behind Google
Explore the journey of Larry Page from a tech-savvy youth to co-founding Google and leading Alphabet.
24 Apr 2024
Mark Leonard: The Mysterious Brain Behind Constellation Software
Information about Mark Leonard is scarce, and one of the only ways to “get to know” him is through his shareholder letters. Join us in an attempt to do so.
24 Apr 2024
Ticker symbol
Country
🇸🇪 Sweden